Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010 –2014

The in vitro activity of oritavancin was assessed against 44,715 gram-positive pathogens causing infections in European and United States (US) hospitals (2010 –2014). There were no substantive differences (>±2-fold dilution) in oritavancin MIC50 or MIC90 values for different species/organism groups over time or by region. Oritavancin (99.9% susceptible) showed modal MIC, MIC50, and MIC90 results of 0.03, 0.03, and 0.06–0.12 mg/L when tested against Staphylococcus aureus, regardless of methicillin su sceptibility, year, or region.
Source: Diagnostic Microbiology and Infectious Disease - Category: Microbiology Authors: Source Type: research